# Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia

> **NCT03118466** · PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 41 (actual)

## Conditions studied

- AML

## Interventions

- **DRUG:** Etoposide
- **DRUG:** Cytarabine
- **DRUG:** Lenalidomide
- **DRUG:** Mitoxantrone

## Key facts

- **NCT ID:** NCT03118466
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-25
- **Primary completion:** 2019-08-29
- **Final completion:** 2021-08-18
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2025-10-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03118466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03118466, "Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03118466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*